ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ABL1 gene mutations causes resistance to tyrosine kinase inhibitors which have been found to improve the management of chronic myeloid leukemia in humans (Shah et al., 2002; O'Hare et al., 2007).